Frost & Sullivan has released an analysis that indicates novel technologies and lower costs for mattress replacements are shifting consumers from specialty bed systems and overlays. To provide more therapeutic value to the end users at affordable costs, mattress replacements are becoming more technologically advanced. The data indicate that the US specialty bed and support surface market for wound management is likely to grow due to an increasing prevalence of pressure ulcers and costs associated with treatment and prevention.
To receive a virtual brochure on this latest analysis, contact Melina Trevino at [email protected] with the following information: name, company, name, title, full address including country, telephone number, and e-mail address.
Uroplasty, Inc, Minneapolis, MN, has received clearance from the US Food and Drug Administration to market in the United States its Urgent PC Neuromodulation System for the treatment of overactive bladder symptoms. The nonsurgical nerve stimulation device is a minimally invasive therapy alternative that is both clinically effective and cost-effective, according to the manufacturer. It is designed for the office-based treatment of overactive bladder, symptoms of urge incontinence, urinary urgency, and urinary frequency.
[black up pointing small triangle] Information:http://www.uroplasty.com
Cardium Therapeutics, Inc, San Diego, CA, has acquired the wound healing technology and related assets of the Tissue Repair Co, San Diego, CA, a company that develops growth factor therapeutics for the potential treatment of tissue wounds, such as diabetic foot ulcers. In the transaction, Cardium acquired Excellarate, a DNA-activated collagen gel for topical treatment that is formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-B.
Currently, the product is being developed as a single administration for the treatment of nonhealing, neuropathic diabetic foot ulcers. Excellarate is designed to stimulate angiogenesis and granulation tissue formation.
[black up pointing small triangle] Information:http://www.cardiumthx.com
Diversified Clinical Services, Jacksonville, FL, a disease management company that works with hospitals to establish and manage comprehensive outpatient wound care programs, has signed 16 new hospital contracts. The new wound care centers will be located in Danbury, CT; Savannah, GA; Crystal River, FL; Statesboro, GA; Bronx, NY; Clifton Springs, NY; Cary, NC; Mooresville, NC; Raleigh, NC; Ashland, OR; Reading, PA; Aiken, SC; Denton, TX; Houston, TX; San Antonio, TX; and Stephenville, TX. Diversified Clinical Services now has 152 hospital partnerships in 36 states.
[black up pointing small triangle] Information:http://www.diversifiedclinicalservices.com
In response to a 2006 Food and Drug Administration advisory about the dangers of potential overdosing and incorrect administration of benzocaine products, HEALTHPOINT, Fort Worth, TX, says that its product, Exactacain, may reduce these risks. This proprietary topical spray anesthetic (benzocaine 14%, butamben 2%, tetracaine hydrochloride 2%) is delivered via a metered spray system to provide precision dosing, according to the manufacturer. Exactacain is indicated for the production of anesthesia of all accessible mucous membranes except the eyes.
[black up pointing small triangle] Information:http://www.healthpoint.com
Barrier Therapeutics, Princeton, NJ, has received approval from the US Food and Drug Administration to use Xolegel Gel 2% for the treatment of seborrheic dermatitis in immunocompetent adults and children age 12 and older. The antifungal agent is a topical form of 2% ketoconazole in a waterless gel for once-daily application. Xolegel is the first prescription gel formulation of ketoconazole approved in the United States.
[black up pointing small triangle] Information:http://www.barriertherapeutics.com
Noble Biomaterials, Scranton, PA, has formed a partnership with Druzak Medical, Inc, Aliquippa, PA, a distributor of medical products used by long-term-care facilities and home health suppliers. Druzak will distribute Noble Biomaterials' SilverSeal products, which use the X-Static silver technology to provide continuous, sustained release of silver cations for broad-spectrum wound care. Noble Biomaterials recently received 7 Food and Drug Administration approvals for SilverSeal wound care medical products, including wound contact dressing, burn contact dressing, hydrogel, hydrocolloid, cast component, ortho component, and bandages.
[black up pointing small triangle] Information:http://www.noblebiomaterials.com